IP strategy

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

China Literature projects 750-850 million yuan loss in 2025, driven by 1.8 billion yuan goodwill impairment and 24% core revenue decline amid intensifying competition.